FDA 连发多份 CRL，开年大批新药上市申请已遭拒_老虎社区_美港股上老虎

FDA 连发多份 CRL，开年大批新药上市申请已遭拒

制药网03-11

2026年以来，全球医药企业就遭遇了FDA的CRL风暴。从罕见病药物到儿童用药，从疗效证据到生产合规，FDA的拒批理由呈现多元化、精细化的特征。近日，Incyte公司收到了FDA发出了一封完整回复函(CRL)，拒绝批准其PD-1抑制剂Zynyz联合铂类化疗用于非小细胞肺癌(NSCLC)一线治疗的补充生物制品许可申请(sBLA)。此次申请被拒，与第三方制造商的生产设施检查问题相关——该设施原为...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2618157119?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-11 14:39","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2618157119","market":"us","top_or_hot":-1,"title":"FDA 连发多份 CRL，开年大批新药上市申请已遭拒","media":"制药网","content":"<div>\n<p>2026年以来，全球医药企业就遭遇了FDA的CRL风暴。从罕见病药物到儿童用药，从疗效证据到生产合规，FDA的拒批理由呈现多元化、精细化的特征。近日，Incyte公司收到了FDA发出了一封完整回复函(CRL)，拒绝批准其PD-1抑制剂Zynyz联合铂类化疗用于非小细胞肺癌(NSCLC)一线治疗的补充生物制品许可申请(sBLA)。此次申请被拒，与第三方制造商的生产设施检查问题相关——该设施原为...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311144149a6b747a8&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA 连发多份 CRL，开年大批新药上市申请已遭拒</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA 连发多份 CRL，开年大批新药上市申请已遭拒\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-11 14:39 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311144149a6b747a8&s=b><strong>制药网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>2026年以来，全球医药企业就遭遇了FDA的CRL风暴。从罕见病药物到儿童用药，从疗效证据到生产合规，FDA的拒批理由呈现多元化、精细化的特征。近日，Incyte公司收到了FDA发出了一封完整回复函(CRL)，拒绝批准其PD-1抑制剂Zynyz联合铂类化疗用于非小细胞肺癌(NSCLC)一线治疗的补充生物制品许可申请(sBLA)。此次申请被拒，与第三方制造商的生产设施检查问题相关——该设施原为...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311144149a6b747a8&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVOH","symbol_name":"Novo Nordisk A/S B Shares ADRhedged","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311144149a6b747a8&s=b","article_id":"2618157119","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311144149a6b747a8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2618157119","pubTimestamp":1773211194,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"2026年以来，全球医药企业就遭遇了FDA的CRL风暴。2月14日消息，Disc Medicine备受瞩目的候选药物Bitopertin用于治疗罕见血液病红细胞生成性卟啉症的上市申请遭到FDA拒绝。2月3日，阿斯利康公告称，美国FDA就Saphnelo用于成人系统性红斑狼疮患者皮下给药的生物制品许可申请发出完整答复函，驳回了其狼疮治疗药物的自行注射剂型上市申请。总的来说，2026 年 开年以来，已有众多新药上市申请被拒。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"NVOH":"Novo Nordisk A/S B Shares ADRhedged","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4588":"碎股","NVOX":"2倍做多NVO ETF-Defiance","LU0128526141.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" ACC","BK4007":"制药","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","BK4121":"生命科学工具和服务","LU0757428866.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AE\" (USD) ACC","BK4599":"减肥药","BK4532":"文艺复兴科技持仓","IE00BFMHRM44.USD":"NEUBERGER BERMAN GLOBAL EQUITY MEGATRENDS \"A\" (USD) ACC","REGN":"再生元制药公司","LU0390134368.USD":"FRANKLIN GLOBAL GROWTH \"A\" (USD) ACC","NVO":"诺和诺德","LU1815336091.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AUP\" (USD) INC","INCY":"因塞特医疗","BK4585":"ETF&股票定投概念","LU0029874061.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" YDIS INC","AZN":"阿斯利康","BK4530":"医药外包概念","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1"},"translate_title":"The FDA has issued multiple CRLs in succession, and a large number of new drug applications have been rejected at the beginning of the year","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVOH":0.6,"NVOX":0.6,"REGN":1.85,"INCY":1.86,"NVO":0.9,"AZN":1.87},"content_text":"2026年以来，全球医药企业就遭遇了FDA的CRL风暴。从罕见病药物到儿童用药，从疗效证据到生产合规，FDA的拒批理由呈现多元化、精细化的特征。近日，Incyte公司收到了FDA发出了一封完整回复函(CRL)，拒绝批准其PD-1抑制剂Zynyz联合铂类化疗用于非小细胞肺癌(NSCLC)一线治疗的补充生物制品许可申请(sBLA)。此次申请被拒，与第三方制造商的生产设施检查问题相关——该设施原为Catalent  Indiana工厂所有，其在2024年12月被诺和诺德以165亿美元收购后归入旗下。值得一提的是，受该工厂波及，再生元也有两款药物被拒批，包括CD20xCD3双抗OdronextamabBLA申请【用于治疗复发或难治性滤泡性淋巴瘤(FL)和弥漫性大B细胞淋巴瘤(DLBCL)】)以及预填充注射器版本HD Eylea的补充上市申请(sBLA)。2月14日消息，Disc Medicine备受瞩目的候选药物Bitopertin用于治疗罕见血液病红细胞生成性卟啉症的上市申请遭到FDA拒绝。据悉，Bitopertin是一种口服小分子GlyT1(甘氨酸转运蛋白1)抑制剂，正在开发用于治疗红细胞生成性卟啉病(EP)。早在今年1月，该药的审评进程就已出现波折：审评周期被延长两周，理由是疗效数据存疑及潜在滥用风险。2月3日，阿斯利康公告称，美国FDA就Saphnelo(阿伏利尤单抗)用于成人系统性红斑狼疮患者皮下给药的生物制品许可申请发出完整答复函(CRL)，驳回了其狼疮治疗药物的自行注射剂型上市申请。Saphnelo用于治疗系统性红斑狼疮，该疾病是一种自身免疫性疾病，患者的免疫系统会错误攻击自身健康组织。该药物目前已有静脉注射剂型获批上市，患者需每四周前往医院或诊所接受静脉注射治疗。此次FDA未批准的主要原因涉及药学、制造及质量控制方面的审评问题，包括制剂稳定性与生产工艺一致性等技术细节。对此，阿斯利康表示，目前仍在与监管机构沟通，推进该申请的审批进程。2月1日，生物制药公司Pharming Group宣布，美国FDA已正式拒绝其核心药物Joenja®(leniolisib)的补充新药申请(sNDA)。据了解，Pharming Group此次申请的核心目标，是将Joenja的适用人群拓展至4至11岁的活化磷酸肌醇3-激酶δ综合征(APDS)儿童患者。FDA拒批的理由，主要集中在药代动力学数据与生产测试方法两大层面。……总的来说，2026 年 开年以来，已有众多新药上市申请被拒。业内认为，这意味着FDA正在加强对临床试验设计科学性和严谨性的要求，尤其是在加速审批通道中，监管重点更加倾向于数据的可重复性、患者人群的代表性，以及治疗作用机制的清晰界定。对于药企而言，需从 “冲刺申报” 转向 “稳健开发”，并将 FDA 要求嵌入研发全流程。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}